Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PharmaCyte BiotechPMCB +0.15%34 Equity-to-Asset is 0.75 as of Apr. 2026, which is 17% below its 10-year median of 0.90. GuruFocus rates PMCB with a GF Score™ of 34/100. The stock has 2 warning signs investors should review. Among 1,411 Biotechnology companies, PharmaCyte Biotech ranks better than 58.75% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
PharmaCyte Biotech Equity-to-Asset Related Terms
PharmaCyte Biotech Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for PharmaCyte Biotech's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PMCB vs NIKI, IMNN, AIM: Equity-to-Asset Comparison
For the Biotechnology subindustry, PharmaCyte Biotech's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmaCyte Biotech Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PharmaCyte Biotech's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where PharmaCyte Biotech's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
PharmaCyte Biotech's Equity to Asset Ratio for the fiscal year that ended in Apr. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PharmaCyte Biotech (PMCB) has a Equity-to-Asset of 0.75 as of Apr. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on PharmaCyte Biotech and its competitors. This is 17% below median its historical median of 0.90. Over the past decade, PharmaCyte Biotech's Equity-to-Asset has ranged from 0.66 to 0.99. According to the industry distribution chart, PharmaCyte Biotech ranks #582 out of 1411 companies in the Biotechnology industry, placing it in the top 41.2%.
Is PharmaCyte Biotech's Equity-to-Asset too high?
PharmaCyte Biotech's current Equity-to-Asset of 0.75 is 17% below median its 10-year median of 0.90. Over the past 10 years, this metric has ranged from a low of 0.66 to a high of 0.99. The Biotechnology industry median Equity-to-Asset is 0.68. PharmaCyte Biotech's value of 0.75 is 10.3% above this industry median. Based on the distribution chart, PharmaCyte Biotech ranks #582 out of 1411 companies in the Biotechnology industry, which is above the industry midpoint. Overall, PharmaCyte Biotech has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does PharmaCyte Biotech's Equity-to-Asset compare to NIKI and IMNN?
According to the Biotechnology industry distribution chart, PharmaCyte Biotech ranks #582 out of 1411 companies for Equity-to-Asset. This puts PharmaCyte Biotech in the upper half of its industry. The industry median Equity-to-Asset is 0.68. PharmaCyte Biotech's value of 0.75 is 10.3% above this benchmark. Historically, PharmaCyte Biotech's own Equity-to-Asset has ranged from 0.66 to 0.99 over the past decade. While the company's 10-year median is 0.90 vs. the industry median of 0.68, PharmaCyte Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PharmaCyte Biotech's current Equity-to-Asset of 0.75 is 10.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on PharmaCyte Biotech and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmaCyte Biotech's current Equity-to-Asset is 0.75, which is 17% below median its own 10-year median of 0.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCyte Biotech stock overvalued right now?
PharmaCyte Biotech (PMCB) has a current Equity-to-Asset of 0.75. The current Equity-to-Asset is 0.75, which is 17% below median its 10-year median of 0.90 and 10.3% above the Biotechnology industry median of 0.68. PharmaCyte Biotech's overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For PharmaCyte Biotech (PMCB), the current Equity-to-Asset is 0.75 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
34GF Score
Get the complete analysis for PMCB
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PMCB has been successfully added to your 
